Tue, Jun 23 · 9:00

Inspired by the reinvigoration the field has seen over the last 2 years, the Targeted Radiopharmaceuticals (TRP) Summit is the primary platform for industry-led discussion of the challenges and opportunities facing developers of theranostic radio ligand therapies.

Join your peers from the likes of Merck, Ipsen, Advanced Accelerator Applications, ETH Zurich, Johns Hopkins Medicine and more to explore the full potential of theragnostic radionuclide therapies within advanced oncology portfolios and gain practical insights on how to deliver meaningful clinical efficacy.

Brochure https://go.evvnt.com/616463-3?pid=5731

Prices:

Conference + 2 Workshops: EUR 3697.0,

Conference + 1 Workshops: EUR 3198.0,

Conference Only: EUR 2699.0,

Workshop Only : EUR 599.0,

Conference + 2 Workshops (Early Bird): EUR 3397.0,

Conference + 1 Workshops (Early Bird): EUR 2948.0,

Conference Only (Early Bird): EUR 2499.0,

Workshop Only (Early Bird): EUR 549.0

Speakers: Jens Kaufmann, Managing Director, 1717 Life Science Ventures, Chris Leamon, Indiana Site Head, Vice President of Discovery Research, Advanced Accelerator Applications, Maurizio Mariani, Head of Research and Development, Advanced Accelerator Applications, Valerie Hergott, Director of Radiopharmaceutical Development and Supply at Centre for Probe Development and Commercialization, Centre for Probe Development and Commercialization, Cristina Mueller, Principal Investigator, ETH Zurich, Linjing Mu, Investigator, ETH Zurich, Tom Christian Holm Anderson, PI 180 ºN, the Norwegian Nuclear Medicine Consortium Chief Radiochemist and Production Manager Centre for Nuclear Medicine and PET Department of Radiology, Haukeland University Hospital, Alice Trehorel, Clinical Supply Chain Coordinator, Ipsen, Joao Osso, Section Head, International Atomic Energy Authority (IAEA), Alberto Andrighetto, Primo Technilogo, Istituto Nazionale di Fisica Nucleare, John Carney, Chief Executive Officer, iTheranostics AG, George Sgouros, Director, Radiological Physics Division, Professor of Radiology and Radiological Science, Johns Hopkins Medicine, Ivan Diaz-Padilla, Executive Director – Medical, Merck KGaA, Oliver Sartor, Professor of Medicine Medical Director, Tulane Cancer Center; C. E. and Bernadine Laborde Professor of Cancer Research, Alison Armour, Independent, Chris Behrenbruch, CEO, Telix Pharmaceuticals, Dan Stevens, Chief Medical Officer, Theragnostics, Greg Mullen, Chief Executive Officer, Theragnostics, Willie Regits, NIST Radioisotope Measurment Assurance Program, U.S. Radioisotope Metrology Associates, Rune Sundset, Director Of The Pre- Clinical Unit, University of Tromsø - The Arctic University of Norway (UiT), Markus Luster, Chair of the Department of Nuclear Medicine, University Hospital Marburg